NCT04118868 2022-10-12
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
Sorrento Therapeutics, Inc.
Phase 1 Unknown
Clinical Trials
4 trialsNCT02542124 2018-11-16
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)
Neumedicines Inc.
Phase 2 Unknown
NCT02943642 2016-10-25
Resimmune®
Angimmune LLC
Phase 2 Unknown
NCT02213861 2016-10-20
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
TetraLogic Pharmaceuticals
Phase 2 Unknown